AIM： To determine the effects of the calcineurin inhibitors, cyclosporine and tacrolimus, on hepatitis C virus （HCV） replication and activity of recurrent hepatitis C in patients post liver transplantation. METHODS...AIM： To determine the effects of the calcineurin inhibitors, cyclosporine and tacrolimus, on hepatitis C virus （HCV） replication and activity of recurrent hepatitis C in patients post liver transplantation. METHODS： The data of a cohort of 107 patients who received liver transplantation for HCV-associated liver cirrhosis between 1999 and 2003 in our center were retrospectively analyzed. The level of serum HCV-RNA and the activity of recurrent hepatitis were compared between 47 patients who received either cyclosporine or tacrolimus as the primary immunosuppressive agent and an otherwise similar immunosuppressive regimen which did not lead to biliary complications within the first 12 mo after transplantation. RESULTS： HCV-RNA increased within 3 mo after transplantation but the differences between the cyclosporine group and the tacrolimus group were insignificant （P=0.49 at 12 too）. In addition, recurrent hepatitis as determined by serum transarninases and histological grading of portal inflammation and fibrosis showed no significant difference after 12 mo （P= 0.34）.CONCLUSION： Cyclosporine or tacrolimus as a primary immunosuppressive agent does not influence the induction or severity of recurrent hepatitis in HCV- infected patients after liver transplantation.展开更多
丙型肝炎是由丙型肝炎病毒(hepatitis C virus,HCV)引起的传染病,主要通过血液传播。我国平均感染率为3.2%。北方稍高,约为4.6%,南方为2.6%～2.9%,感染人数估计有3 700万。受感染的母亲传播给婴儿的发生率为5%。丙肝是严重威胁人类健康...丙型肝炎是由丙型肝炎病毒(hepatitis C virus,HCV)引起的传染病,主要通过血液传播。我国平均感染率为3.2%。北方稍高,约为4.6%,南方为2.6%～2.9%,感染人数估计有3 700万。受感染的母亲传播给婴儿的发生率为5%。丙肝是严重威胁人类健康的传染病之一,多数患者可以演变为慢性丙型肝炎,其中20%左右可发展为肝硬化,肝硬化患者10年内有大约30%发展为终末期肝病,并且HCV感染与原发肝癌有较密切关系。随着医学检测方法的不断进展,丙肝检测方法也有了很大的进展。本文对丙肝检测方法进行了综述。从胶体金法、ELISA法(丙肝抗体检测)、丙肝抗原检测和分子生物学的诊断几个方面进行阐述。目前临床对丙型肝炎的诊断仍是以临床症状结合抗-HCV抗体、HCV-RNA等实验室指标为临床诊断依据。展开更多
丙型肝炎由丙型肝炎病毒(hepatitis C virus,HCV)感染引起,主要经血液传播,有6种主要的基因型.感染者呈全球分布,我国属中、高流行区.丙型肝炎易慢性化发展为肝硬化、肝癌.HCV-RNA及基因型的检测对于丙型肝炎的诊断及治疗有着重要作用....丙型肝炎由丙型肝炎病毒(hepatitis C virus,HCV)感染引起,主要经血液传播,有6种主要的基因型.感染者呈全球分布,我国属中、高流行区.丙型肝炎易慢性化发展为肝硬化、肝癌.HCV-RNA及基因型的检测对于丙型肝炎的诊断及治疗有着重要作用.目前聚乙二醇干扰素α(polyethylene glycol interferon α,PEG-IFN-α)与利巴韦林(Ribavirin,RBV)的联合治疗为抗HCV治疗的标准治疗(SOC)方案,研究热点为基于SOC方案上的应答指导治疗(responsible guide treat,RGT)、新研发的小分子药物的单独应用及其与SOC的联合应用.本文就这些问题作简要综述.展开更多
AIM:To test whether in vitro incubation of peripheral blood mononuclear cells (PBMC) with interferon (IFN) could efficiently decrease hepatitis C virus-RNA (HCV-RNA) amount and to analyze whether this effect was assoc...AIM:To test whether in vitro incubation of peripheral blood mononuclear cells (PBMC) with interferon (IFN) could efficiently decrease hepatitis C virus-RNA (HCV-RNA) amount and to analyze whether this effect was associated with clinical response to IFN.METHODS:Twenty-seven patients with histologically proven chronic hepatitis C were given intravenous administration of 6 million units (MU) IFN-β daily for 6 weeks followed by three times weekly for 20 weeks. PBMC collected before IFN therapy were incubated with IFN-β and HCV-RNA in PMBC was semi-quantitatively determined.RESULTS: Twenty-five patients completed IFN therapy.Eight patients (32%) had sustained loss of serum HCV-RNA with normal serum ALT levels after IFN therapy (complete responders).HCV-RNA in PBMC was detected in all patients,whereas it was not detected in PBMC from healthy subjects.In vitro administration of IFN-β decreased the amount of HCV-RNA in PMBC in 18 patients (72%). Eight of these patients obtained complete response. On the other hand,none of the patients whose HCV-RNA in PBMC did not decrease by IFN-β was complete responders. Multiple logistic regression analysis revealed that the decrease of HCV-RNA amount in PBMC by IFN-β was the only independent predictor for complete response (P<0.05).CONCLUSION:The effect of in vitro IFN-β on HCV in PBMC reflects clinical response and would be taken into account as a predictive marker of IFN therapy for chronic hepatitis C.展开更多
文摘AIM： To determine the effects of the calcineurin inhibitors, cyclosporine and tacrolimus, on hepatitis C virus （HCV） replication and activity of recurrent hepatitis C in patients post liver transplantation. METHODS： The data of a cohort of 107 patients who received liver transplantation for HCV-associated liver cirrhosis between 1999 and 2003 in our center were retrospectively analyzed. The level of serum HCV-RNA and the activity of recurrent hepatitis were compared between 47 patients who received either cyclosporine or tacrolimus as the primary immunosuppressive agent and an otherwise similar immunosuppressive regimen which did not lead to biliary complications within the first 12 mo after transplantation. RESULTS： HCV-RNA increased within 3 mo after transplantation but the differences between the cyclosporine group and the tacrolimus group were insignificant （P=0.49 at 12 too）. In addition, recurrent hepatitis as determined by serum transarninases and histological grading of portal inflammation and fibrosis showed no significant difference after 12 mo （P= 0.34）.CONCLUSION： Cyclosporine or tacrolimus as a primary immunosuppressive agent does not influence the induction or severity of recurrent hepatitis in HCV- infected patients after liver transplantation.
文摘丙型肝炎是由丙型肝炎病毒(hepatitis C virus,HCV)引起的传染病,主要通过血液传播。我国平均感染率为3.2%。北方稍高,约为4.6%,南方为2.6%～2.9%,感染人数估计有3 700万。受感染的母亲传播给婴儿的发生率为5%。丙肝是严重威胁人类健康的传染病之一,多数患者可以演变为慢性丙型肝炎,其中20%左右可发展为肝硬化,肝硬化患者10年内有大约30%发展为终末期肝病,并且HCV感染与原发肝癌有较密切关系。随着医学检测方法的不断进展,丙肝检测方法也有了很大的进展。本文对丙肝检测方法进行了综述。从胶体金法、ELISA法(丙肝抗体检测)、丙肝抗原检测和分子生物学的诊断几个方面进行阐述。目前临床对丙型肝炎的诊断仍是以临床症状结合抗-HCV抗体、HCV-RNA等实验室指标为临床诊断依据。
文摘AIM:To test whether in vitro incubation of peripheral blood mononuclear cells (PBMC) with interferon (IFN) could efficiently decrease hepatitis C virus-RNA (HCV-RNA) amount and to analyze whether this effect was associated with clinical response to IFN.METHODS:Twenty-seven patients with histologically proven chronic hepatitis C were given intravenous administration of 6 million units (MU) IFN-β daily for 6 weeks followed by three times weekly for 20 weeks. PBMC collected before IFN therapy were incubated with IFN-β and HCV-RNA in PMBC was semi-quantitatively determined.RESULTS: Twenty-five patients completed IFN therapy.Eight patients (32%) had sustained loss of serum HCV-RNA with normal serum ALT levels after IFN therapy (complete responders).HCV-RNA in PBMC was detected in all patients,whereas it was not detected in PBMC from healthy subjects.In vitro administration of IFN-β decreased the amount of HCV-RNA in PMBC in 18 patients (72%). Eight of these patients obtained complete response. On the other hand,none of the patients whose HCV-RNA in PBMC did not decrease by IFN-β was complete responders. Multiple logistic regression analysis revealed that the decrease of HCV-RNA amount in PBMC by IFN-β was the only independent predictor for complete response (P<0.05).CONCLUSION:The effect of in vitro IFN-β on HCV in PBMC reflects clinical response and would be taken into account as a predictive marker of IFN therapy for chronic hepatitis C.
